Tempus AI Stock (TEM) Could See ‘Tesla or Nvidia-Type Inflection,' Claims Short Seller
AI (TEM) came under intense pressure after a scathing short seller report raised red flags about the company's valuation, business model, and financial transparency. The bearish hedge fund Spruce Point Capital report compared TEM stock's potential trajectory to tech names like Tesla (TSLA) and Nvidia (NVDA), warning investors of a looming 'inflection point.'
Confident Investing Starts Here:
Tempus AI specializes in data-driven solutions for the healthcare industry with a focus on oncology and genomics.
TEM Stock Rattled by Explosive Short Seller Claims
The Spruce report warns of a potential 50% to 60% long-term downside for TEM stock and a high risk of market underperformance. The firm argued that Tempus' growth story is largely driven by hype and retail investor enthusiasm, fueled by the company's positioning as an exciting AI-driven tech disruptor. However, Spruce Point cautioned investors to look past the buzz, pointing instead to concerns over aggressive accounting practices, financial engineering, related-party transactions, and overall earnings quality.
The report also criticized the company's billing practices, highlighting an aggressive use of billing code 81479, known for minimal oversight and a higher risk of misuse. According to the report, this approach could artificially boost revenue, potentially prioritizing financial gains over patient care. Additionally, the report raised concerns about Tempus AI's leadership, pointing to CEO Eric Lefkofsky's past involvement with companies that faced financial scandals, including bankruptcies and restatements.
Following these claims, TEM stock crashed over 19% on Wednesday. Still, despite the sharp drop, the stock remains up 58% year-to-date.
Tempus Rejects Short-Seller Claims
Tempus AI dismissed the short-seller allegations, calling the report 'riddled with hypotheticals and inaccuracies' and failing to reflect the company's solid track record of financial performance and growth.
Is Tempus a Good Stock to Buy?
There's no denying the risks with Tempus AI. But Spruce Point's report doesn't introduce any new red flags; it simply amplifies existing concerns.
On TipRanks, TEM stock has received a Moderate Buy rating based on six Buy and three Hold recommendations. The Tempus AI share price forecast is $66.25, which implies an upside of 25% from the current level.
See more TEM analyst ratings
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
33 minutes ago
- Globe and Mail
Better High-Yield Dividend Stock to Buy Now: Pfizer vs. Prologis
Investors looking for sources of passive income to fuel their retirement dreams face a dilemma. Should you chase high yields from slow-growing businesses or invest in lower-yield providers with more predictable cash flows? Lately, Pfizer (NYSE: PFE) and Prologis (NYSE: PLD) have been perfect examples of the trade-off between attractive yields and dividend growth. Pfizer offers a sky-high yield that's climbing slowly. Prologis offers a much lower yield, but it's been raising its payout at a remarkable pace. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Here's a closer look at both to help you decide which one fits your goals. Pfizer Shares of Pfizer have fallen about 62% from their COVID-19 pandemic highs. The stock is way down, but the company has raised its payout every year since 2009. At its beaten-down price, this stock offers an eye-popping 7.3% dividend yield. Pfizer's COVID-19 vaccine, Comirnaty, and antiviral treatment, Paxlovid, drove adjusted earnings up to $6.58 per share in 2022. Sinking demand for COVID-19 vaccines and treatments reduced adjusted earnings to just $3.11 per share last year. In 2025, Pfizer expects a significant earnings contraction. At the midpoint of the guided range management provided this April, adjusted earnings are expected to fall by 6.8% this year. The $2.80 per share management expects at the low end of the guided range is more than enough to support a dividend payout currently set at an annualized $1.72 annually, but there could be further contractions ahead. Eliquis is a next-generation blood thinner that Pfizer markets in collaboration with Bristol Myers Squibb. It's currently responsible for 14% of Pfizer's total revenue and is likely to lose ground to generic competition in the lucrative U.S. market in 2028. Long before Eliquis loses ground to generic competition, the company's lead growth driver, Vyndaquel, could stumble. BridgeBio launched a competing treatment called Attruby in late 2024, and it's been exceeding expectations. Pfizer's facing patent cliffs, but it also has one of the most productive development pipelines in the industry. Last year alone, the Food and Drug Administration issued more than a dozen approvals to new Pfizer treatments and several that are already on the market. With plenty of new products to market, the drugmaker has a good chance to continue its payout-raising streak in the decade ahead. Prologis As more folks do their shopping online, demand for warehouses that can support e-commerce has soared. By anticipating the demand, Prologis has become the world's largest real estate investment trust (REIT) that everyday investors can buy shares of. Fear and uncertainty regarding the taxes businesses need to pay when importing goods to the U.S. have pressured the stock. It's down about 12% from a peak it set in March. At its beaten-down price, it offers a 3.7% yield. Prologis has been able to raise its dividend by 11.7% annually over the past five years. At this pace, investors who buy at recent prices could begin receiving a double-digit yield on cost in less than a decade. Amazon, Home Depot, and FedEx are Prologis' largest customers. These three tenants are responsible for only 8.2% of the rent payments Proligis receives every month. This high level of diversification is a big reason it can boast industry-leading credit ratings. With an A2 rating from Moody's and an A rating from S&P Global, the weighted average interest rate on Prologis' outstanding debts was just 3.1% at the end of March. Acquiring and developing properties is an important part of this REIT's business, but it also acts as a lender. With an enviable credit rating, it can produce a strong profit while offering rates that its smaller competitors can't match. For companies that own their warehouses, selling them to Prologis and leasing them back is often their lowest-cost source of capital. With the vast majority of the world's logistics real estate still owned by the companies that use it, Prologis could continue growing at a rapid pace for decades to come. Pfizer offers a yield that's almost twice as high as Prologis's, but the pharmaceutical giant has been raising its payout at less than half the pace of the logistics REIT. Pfizer might be a good option for folks near retirement age. For income-seeking investors, though, Prologis seems like the better dividend stock to buy now. Should you invest $1,000 in Prologis right now? Before you buy stock in Prologis, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Prologis wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $656,825!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $865,550!* Now, it's worth noting Stock Advisor 's total average return is994% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Cory Renauer has positions in Amazon. The Motley Fool has positions in and recommends Amazon, Bristol Myers Squibb, FedEx, Home Depot, Moody's, Pfizer, Prologis, and S&P Global. The Motley Fool recommends BridgeBio Pharma and recommends the following options: long January 2026 $90 calls on Prologis. The Motley Fool has a disclosure policy.
Globe and Mail
39 minutes ago
- Globe and Mail
2 AI Growth Stocks That Could Help Set You Up for Life
The artificial intelligence (AI) market has grown like a weed over the past decade. That rapid expansion -- which was fueled by more sophisticated cloud computing services, large language models, and generative AI applications -- lit a blazing fire under some high-growth tech stocks. The most obvious winners are Nvidia, the world's top producer of discrete graphics processing units (GPUs) for processing AI tasks; and Microsoft, which acquired a big stake in OpenAI and integrated the start-up's AI tools into its own services. But there are still plenty of other under-the-radar AI growth plays that might have more upside potential. Let's look at two of them: Credo Technology (NASDAQ: CRDO) and Arm Holdings (NASDAQ: ARM). Credo Technology Credo, which went public in 2022, sells a wide range of high-speed connectivity solutions for the data center, cloud, and AI markets. Its core products include data transfer chips, digital signal processors, line card components, and active electric cables for data centers. From fiscal 2022 to fiscal 2025 (which ended this May), Credo's revenue grew at a compound annual growth rate (CAGR) of 60%. It also turned profitable for the first time in fiscal 2025. Credo attributed that growth to the rapid expansion of the cloud and AI markets, which drove its hyperscale customers to aggressively upgrade their data center infrastructure. Its biggest customer -- widely believed to be Microsoft -- accounted for 39% of its revenue in fiscal 2024. That customer concentration isn't ideal, but it also isn't surprising considering how much Microsoft is prioritizing the expansion of its cloud and AI ecosystems. Its other major customers include Amazon and Tesla. From fiscal 2025 to fiscal 2027, analysts expect Credo's revenue to rise at a CAGR of 47% as its earnings per share (EPS) increase at a CAGR of 113%. That rapid growth could be driven by the continued expansion of the AI market, and a shift toward higher-speed ethernet connections that will spur demand for its new optical modules. There's also rising demand for its "chiplet" designs, which are more modular, customizable, and scalable than monolithic system on chips (SoCs), which merge together multiple chips on a single die. It isn't cheap at 64 times this year's earnings, but it could have plenty of room to run over the next few decades. Arm Holdings Arm is a U.K. chip designer which was acquired by Japan's SoftBank in 2016 and spun off again in a second IPO in 2023. It develops power-efficient CPUs that consume less power than the x86 CPUs produced by Intel and AMD. That makes Arm's chips well-suited for smartphones, tablets, Internet of Things (IoT) gadgets, connected vehicles, and even some notebook computers and servers. Its chip designs are now installed in approximately 99% of the world's smartphones, and most of its growth over the past few years has been fueled by its AI-optimized Armv9 designs. Arm's revenue rose 24% in fiscal 2025 (which ended this March), and analysts expect that figure to grow at a CAGR of 21% over the next three years. Its EPS, which surged 159% in fiscal 2025, is expected to grow at a CAGR of 41% through fiscal 2028. Arm originally only generated its revenue by licensing its designs to chipmakers like Qualcomm, MediaTek, and Apple instead of producing its own chips. But earlier this year, it announced that it would start developing its own first-party chips and outsource its production to Taiwan Semiconductor Manufacturing. That surprising move would boost Arm's operating expenses and turn it into a direct competitor for some of its top clients. But it could also undercut other Arm-based chips because it doesn't need to pay any royalties or licensing fees for its own designs. Its first-party brand recognition could also make it a more appealing option than third-party Arm-based chips for OEMs. Arm's stock certainly isn't cheap at 113 times this year's earnings, but it could be a great long-term play on the market's growing demand for more power-efficient AI chips. Should you invest $1,000 in Credo Technology Group right now? Before you buy stock in Credo Technology Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Credo Technology Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $656,825!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $865,550!* Now, it's worth noting Stock Advisor 's total average return is994% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Leo Sun has positions in Amazon and Apple. The Motley Fool has positions in and recommends Advanced Micro Devices, Amazon, Apple, Intel, Microsoft, Nvidia, Qualcomm, Taiwan Semiconductor Manufacturing, and Tesla. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft, short August 2025 $24 calls on Intel, and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
Globe and Mail
40 minutes ago
- Globe and Mail
Bitcoin Has Hit an All-Time High of $112,000. 3 Reasons the Leading Cryptocurrency Is Surging.
Last month, Bitcoin (CRYPTO: BTC) reached a new all-time high of $111,970. Even after a small pullback, the leading cryptocurrency is still up 13% this year, while the S&P 500 has gained just 1.6%. Going back even further, Bitcoin has returned an impressive 990% during the past five years. When a cryptocurrency goes on a tear, investors and prospective investors want to know why. And, even more importantly, they want to know if the gains are likely to continue. In Bitcoin's case, there are a few key reasons it has been doing so well lately. 1. A crypto-friendly political climate President Donald Trump was pro-crypto and pro-Bitcoin during his campaign, even saying that he wanted the U.S. to be "the Bitcoin superpower of the world." He was expected to usher in a more crypto-friendly climate if elected, and so far, he has done just that. Under the Biden administration, the Securities and Exchange Commission (SEC) had gone after many of the major crypto companies and exchanges. Trump's pick for SEC Chair, Paul Atkins, is known for supporting cryptocurrency. Since Trump has taken office, the SEC has ended lawsuits with Coinbase Global (NASDAQ: COIN) and Binance and ended investigations into OpenSea, an NFT marketplace; and Uniswap, a decentralized exchange. The Trump administration also announced the creation of a Strategic Bitcoin Reserve in March. Just like countries stockpile gold, foreign currencies, and other valuable assets, the federal government is stockpiling Bitcoin. Arizona and New Hampshire have followed suit with their own Bitcoin reserves. Government support for Bitcoin and cryptocurrency as a whole should be good for the industry, as it helps further legitimize cryptocurrencies as an investment. Since Election Day, Bitcoin has hit multiple all-time highs and is up 54% overall. 2. It's a hedge against a weak U.S. dollar The U.S. dollar has been losing value, with the U.S. Dollar Index (DXY) down about 9% on the year. Import tariffs, the possibility of a trade war, and worries of a recession have all taken their toll. When the dollar declines or there's a period of high inflation, investors often look for alternative assets to use as stores of value. Gold has long been a popular choice, and in recent years, Bitcoin has been called digital gold. There's a limited number of Bitcoin available -- the maximum supply is capped at 21 million coins. This gives it a built-in scarcity that traditional currencies don't have. It's hard to predict currency fluctuations or when the U.S. dollar will bounce back, although a U.S.-China trade deal would probably help. This may not be a long-term tailwind for Bitcoin, but it is a benefit at the moment. 3. It's increasingly popular with institutional investors While institutional investors used to be wary of investing in Bitcoin, that's no longer the case. The SEC approved the first Bitcoin spot price exchange-traded funds (ETFs) in January 2024, opening the door for more institutional adoption. Those U.S. Bitcoin ETFs had inflows of $5.2 billion in May and have over $125 billion in combined assets under management (AUM) at the time of this writing. Like government support, institutional investors help legitimize Bitcoin, and the amount of money they invest can also drive up the price. Bitcoin's value has already jumped by 130% since the approval of Bitcoin ETFs, and cryptocurrency will likely become more and more mainstream going forward. A January survey by EY Parthenon and Coinbase found that 83% of institutional investors were planning to increase their digital asset allocation in 2025. Will Bitcoin continue to surge? All the factors that have contributed to Bitcoin's latest bull run are still in place. The political climate is and should remain positive toward cryptocurrency. Banks, hedge funds, and other institutions are investing in Bitcoin. The U.S. dollar hasn't recovered yet, although that could change at any time. This doesn't mean Bitcoin is a surefire investment. Far from it -- Bitcoin is risky, and you could make a compelling argument against it. Bitcoin has limited utility, transactions are slow and relatively expensive, and it doesn't produce anything of value like a business does. People invest in the hopes that the price will go up. But as it's demonstrated over the years, Bitcoin can deliver incredible returns, and it's the most successful cryptocurrency by a wide margin. Stocks are still a safer choice, but Bitcoin is a good alternative investment for anyone who wants digital assets in their portfolio. Should you invest $1,000 in Bitcoin right now? Before you buy stock in Bitcoin, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bitcoin wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $656,825!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $865,550!* Now, it's worth noting Stock Advisor 's total average return is994% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025
